Sep 3, 2026 · 5 min
Snowflake gains while HPE and Ultragenyx expose market fault lines
Snowflake Jumps, Hewlett Packard Slides, and Ultragenyx Sinks as Rare Disorder Drug Fails Late Stage Trial
The episode shows how investor reactions can diverge sharply when growth, supply constraints, and clinical risk collide.
- 1Snowflake raised its annual sales outlook as rapid adoption of its AI-assisted coding tool CoCo fueled a share-price jump.
- 2Hewlett Packard Enterprise reported higher revenue and improved its forecast, but component shortages continued to constrain sales.
- 3Ultragenyx plunged after its experimental Angelman syndrome treatment failed to meet the primary endpoint in a Phase 3 trial.
Don't miss
Ultragenyx’s sharp selloff after its experimental Angelman syndrome treatment failed in a Phase 3 trial is the episode’s clearest market shock.
The brief
Bloomberg’s Stock Movers Report contrasts three sharply different market reactions: Snowflake rises on stronger expectations, HPE slips despite better figures, and Ultragenyx plunges after a clinical setback.
Snowflake’s annual sales outlook improved as the company highlighted rapid adoption of CoCo, its AI-assisted coding tool, giving investors a growth story tied directly to expanding AI use.
Hewlett Packard Enterprise delivered higher revenue and an improved forecast, but component shortages kept sales constrained, showing why better headline numbers did not translate into a stronger stock.
Ultragenyx suffered the episode’s clearest shock after its experimental Angelman syndrome treatment failed to meet the primary endpoint in a Phase 3 trial.
Together, the moves illustrate three distinct sources of market repricing: accelerating product demand, physical supply limits, and the binary risk of late-stage drug development.
What was said on this episode
2 statements · 2 positive
Snowflake has bucked the broader software-sector volatility trend.
“this is one of the few software companies that's really sort of bucked the trend.”
Listen at 1:06
Snowflake is showing solid results without apparent AI-disruption fears.
“So Snowflake really showing solid, solid results and no fears here, at least, of AI disruption.”
Listen at 1:17
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
SnowflakeListen to the full episode and explore every guest, topic, and moment on PodLume.